Ally Bridge Group (Ny) LLC Trevi Therapeutics, Inc. Transaction History
Ally Bridge Group (Ny) LLC
- $88.1 Million
- Q4 2024
A detailed history of Ally Bridge Group (Ny) LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Ally Bridge Group (Ny) LLC holds 781,489 shares of TRVI stock, worth $3.53 Million. This represents 3.78% of its overall portfolio holdings.
Number of Shares
781,489
Previous 1,322,800
40.92%
Holding current value
$3.53 Million
Previous $4.42 Million
24.65%
% of portfolio
3.78%
Previous 3.14%
Shares
3 transactions
Others Institutions Holding TRVI
# of Institutions
114Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$51.4 Million3.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.7MShares$48.2 Million2.72% of portfolio
-
Viking Global Investors LP4.4MShares$19.9 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$19 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$18.8 Million0.04% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $264M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...